ACHIEVE-3 marca la primera vez que dos terapias orales con GLP-1 se comparan directamente en un estudio clnico fase 3, en el que nuestro GLP-1 oral claramente super a semaglutida oral en los resultados que ms importan a los pacientes con diabetes tipo 2
In 2024 and 2025, an increasing number of cases of ischemic optic neuropathy have been reported through the FDA adverse events reporting system (FAERS) for semaglutide drugs
Alsuwailem OA, Alanazi R, Almutairi HM, Asiree RH, Almutairi W, Almutairi TM, Zamandar A, Alkhames S
Key Takeaway If youre using semaglutide to lose weight or improve metabolic health, adding glycine is a smart, evidence-based move
Medical News Today spoke with five GLP-1 medical experts to find out what exactly is microdosing and how it is different from taking normal amounts of GLP-1 medications, as well as its safety and efficacy
doi.org/10.1186/s12958-018-0343-0 Lisi F, Carfagna P, Oliva MM, et al